-
ACLA Commends the 2023 Omnibus Appropriations Bill
The 2023 Omnibus provides critical relief for labs and patients Washington, D.C. – The American Clinical Laboratory Association (ACLA) commends inclusion in the 2023 Omnibus Appropriations Bill ... Read More -
ACLA Comments on the VALID Act of 2022
-
ACLA Statement on Updated VALID Act Introduced as Part of Senate FDA User Fee Package
Washington, D.C. – In response to the Senate Committee on Health, Education, Labor and Pensions’ (HELP) release of a bipartisan, updated version of the Verifying Accurate Leading-edge IVCT ... Read More -
ACLA Statement on Clinical Use of Non-invasive Prenatal Screenings (NIPS)
Washington, D.C. – In response to recent interest in non-invasive prenatal screenings (NIPS) and their use by patients and health care providers, ACLA has issued the ... Read More -
ACLA Statement on Reintroduction of the VALID Act
Washington, D.C. – Following the reintroduction of the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, ACLA President Julie Khani issued the following statement: ... Read More -
ACLA Comments on MCIT/Reasonable and Necessary Definition Proposed Rule
-
ACLA Comments on Medicare Coverage of Innovative Technology (MCIT)
-
ACLA Comment Letter on NCCI Policy Manual
-
ACLA Response to Cures 2.0
-
ACLA Letter on the Request for Information Regarding the Anti-Kickback Statute and Beneficiary Inducement CMP
